Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol
{{output}}
BACKGROUND: Atorvastatin, a new HMG-CoA reductase inhibitor in clinical development has demonstrated an acceptable safety profile and marked cholesterol and triglyceride reduction at doses ranging from 10-80 mg/day. Since bile acid sequestering resins are ofte... ...
